Allan Rubenstein

Background

About Allan Rubenstein

Dr. Allan E. Rubenstein is a highly experienced public company board director, a successful entrepreneur, and a respected doctor. In medicine and science, he is a neurologist known for his pioneering work on research and treatment of neurofibromatosis,(NF), a rare genetic disorder, and has become expert due to his commercial interests in genomics, ocular conditions and treatments, medical devices and women’s health. He has achieved the trifecta of succeeding in commercial, scientific and medical environments, and in applying critical knowledge between them. Allan served as Vice- Chairman or Lead Independent Director for all but two of his twenty-nine years on the board of The Cooper Companies (NYSE: COO). Early in his career, he applied his medical and scientific knowledge to starting businesses. His first success was founding, growing and selling a mobile CT and MRI scanning company. He next founded and served as CEO of NexGenix Pharma and joined the board of Bioclinica (Nasdaq:BIOC). Most recently he joined the board of Visioneering Technologies (VTI:ASX), a contact lens compony, and is head of the Scientific Advisory Board for Coloursmith, a privately-held company which has a unique technology for wavelength-filtering polymers for contact lenses. In medicine, Allan is considered one of the world’s experts regarding NF. He started the first multidisciplinary clinic devoted to NF in the world at the Mount Sinai School of Medicine, which over the years became the model for more than 150 other NF clinics in the U.S, Europe, and South America. He also co-founded the Children’s Tumor Foundation and served as its medical director for more than two decades. Allan is well-known for his expertise in advancing science through collaborations between the NIH, other government agencies, scientists and donors. He is currently a Clinical Professor of Neurology and Pediatrics at NYU Medical Center and serves on the Advisory Board of the Tufts University Graduate Program in Biomedical Sciences.